Lung Cancer
News
EMA: No Cancer Link for ARBs
News
Chemoradiotherapy Boosts Survival in Elderly NSCLC Patients
Major Finding: Median overall survival was significantly longer at 22.4 months in patients who received chemotherapy and radiation vs. 16.9 months...
News
Iniparib Adds No Survival Benefit in Lung Cancer Trial
Major Finding: Median progression-free survival was 5.7 months with iniparib added to gemcitabine/cisplatin chemotherapy vs.
News
Lower Radiation Dose Improves Lung Cancer Survival
Major Finding: Median overall survival among patients with stage III NSCLC treated with chemotherapy was 20.7 months with high-dose radiation (74...
News
EGFR Assay Vastly Underused in Lung Cancer Patients
Major Finding: Only about 8,000 orders for EGFR assays could be verified in 2010.Data Source: A nationwide map based on a Genzyme company database...
News
Prone Position During Breast Irradiation Lessens Lung Cancer Risk
Major Finding: A prone position for whole breast irradiation was associated with an estimated 1.99% lifetime risk for radiation-associated...
Article
Reduced lung cancer mortality with low-dose computed tomographic screening
Article
To screen, or not to screen
News
Vorinostat Fails as Second-Line Therapy for Mesothelioma
Finding: Overall survival was not significantly different at a median of 31 weeks with vorinostat and 27 weeks with placebo (HR, 0.98; P = .858)....
How We Do It
Guiding Patients Facing Decisions about “Futile” Chemotherapy
News
Pemetrexed/Bevacizumab Maintenance Combo Stalls Lung Cancer
Findings: Patients on the combination maintenance therapy had a median progression-free survival of 10.2 months vs.